<VariationArchive RecordType="classified" VariationID="832181" VariationName="NC_000013.11:g.(?_100301450)_(100425741_?)del" VariationType="Deletion" Accession="VCV000832181" Version="2" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2023-03-26" DateCreated="2020-04-15" MostRecentSubmission="2023-03-26">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="820535" VariationID="832181">
      <GeneList>
        <Gene Symbol="PCCA" FullName="propionyl-CoA carboxylase subunit alpha" GeneID="5095" HGNC_ID="HGNC:8653" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>13q32.3</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="13" Accession="NC_000013.11" start="100089093" stop="100530435" display_start="100089093" display_stop="100530435" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="13" Accession="NC_000013.10" start="100741268" stop="101182690" display_start="100741268" display_stop="101182690" Strand="+" />
          </Location>
          <OMIM>232000</OMIM>
        </Gene>
      </GeneList>
      <Name>NC_000013.11:g.(?_100301450)_(100425741_?)del</Name>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>13q32.3</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" forDisplay="true" AssemblyStatus="previous" Chr="13" Accession="NC_000013.10" innerStart="100953704" innerStop="101077995" display_start="100953704" display_stop="101077995" variantLength="124292" />
      </Location>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000013.10" sequenceAccession="NC_000013" sequenceVersion="10" change="g.(?_100953704)_(101077995_?)del" Assembly="GRCh37">
            <Expression>NC_000013.10:g.(?_100953704)_(101077995_?)del</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NC_000013.11:g.(?_100301450)_(100425741_?)del AND Propionic acidemia" Accession="RCV001032695" Version="2">
        <ClassifiedConditionList TraitSetID="3247">
          <ClassifiedCondition DB="MedGen" ID="C0268579">Propionic acidemia</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2022-09-12" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2022-09-12" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2020-04-15" MostRecentSubmission="2023-03-26">
        <ReviewStatus>criteria provided, single submitter</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">10518292</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">19157943</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">20549364</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">22033733</ID>
        </Citation>
        <DescriptionHistory Dated="2023-03-24">
          <Description>Likely pathogenic</Description>
        </DescriptionHistory>
        <ConditionList>
          <TraitSet ID="3247" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="5805" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Glycinemia, ketotic</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Hyperglycinemia with ketoacidosis and leukopenia</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Ketotic hyperglycinemia</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Propionic acidemia</ElementValue>
                <XRef ID="Propionic+acidemia/5994" DB="Genetic Alliance" />
                <XRef ID="HP:0003571" DB="Human Phenotype Ontology" />
                <XRef ID="MONDO:0011628" DB="MONDO" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">PROP</ElementValue>
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">The spectrum of propionic acidemia (PA) ranges from neonatal-onset to late-onset disease. Neonatal-onset PA, the most common form, is characterized by a healthy newborn with poor feeding and decreased arousal in the first few days of life, followed by progressive encephalopathy of unexplained origin. Without prompt diagnosis and management, this is followed by progressive encephalopathy manifesting as lethargy, seizures, or coma that can result in death. It is frequently accompanied by metabolic acidosis with anion gap, lactic acidosis, ketonuria, hypoglycemia, hyperammonemia, and cytopenias. Individuals with late-onset PA may remain asymptomatic and suffer a metabolic crisis under catabolic stress (e.g., illness, surgery, fasting) or may experience a more insidious onset with the development of multiorgan complications including vomiting, protein intolerance, failure to thrive, hypotonia, developmental delays or regression, movement disorders, or cardiomyopathy. Isolated cardiomyopathy can be observed on rare occasion in the absence of clinical metabolic decompensation or neurocognitive deficits. Manifestations of neonatal and late-onset PA over time can include growth impairment, intellectual disability, seizures, basal ganglia lesions, pancreatitis, and cardiomyopathy. Other rarely reported complications include optic atrophy, hearing loss, premature ovarian insufficiency, and chronic renal failure.</Attribute>
                <XRef ID="NBK92946" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="467" />
                <XRef ID="467" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">22593918</ID>
                <ID Source="BookShelf">NBK92946</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="GMDI/SERN, 2017">
                <URL>https://managementguidelines.net/guidelines.php/104/PROP%20Nutrition%20Guidelines/Version%201.2</URL>
                <CitationText>PROP Nutrition Management Guidelines</CitationText>
              </Citation>
              <Citation Type="Position Statement" Abbrev="HGS Australasia, 2019">
                <URL>https://www.hgsa.org.au/documents/item/8694</URL>
                <CitationText>Policy: Recommendations for Screening for Specific Disorders</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2022">
                <URL>https://www.acmg.net/PDFLibrary/Elevated%20C3%20Acylcarnitine%20PA%20and%20MA.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Newborn Screening ACT Sheet, Elevated C3 Acylcarnitine, Propionic Acidemia (PA) and Methylmalonic Acidemia (MMA), 2022</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2022">
                <URL>https://www.acmg.net/PDFLibrary/C3-Algorithm.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Algorithm, Propionic and Methylmalonic Acidemia: C3 Elevated, 2022</CitationText>
              </Citation>
              <XRef ID="35" DB="Orphanet" />
              <XRef ID="C0268579" DB="MedGen" />
              <XRef ID="MONDO:0011628" DB="MONDO" />
              <XRef Type="MIM" ID="606054" DB="OMIM" />
              <XRef Type="primary" ID="HP:0003571" DB="Human Phenotype Ontology" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="2357257" SubmissionDate="2023-03-21" DateLastUpdated="2023-03-26" DateCreated="2020-04-15">
        <ClinVarSubmissionID localKey="NM_000282.3_Deletion (Exons 13-20)|MedGen:C0268579" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001196002" DateUpdated="2023-03-26" DateCreated="2020-04-15" Type="SCV" Version="2" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2022-09-12">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">19157943</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">10518292</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">20549364</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">22033733</ID>
          </Citation>
          <Comment>This variant is a gross deletion of the genomic region encompassing exon(s) 13-20 of the PCCA gene. This variant would be expected to be in-frame, preserving the integrity of the reading frame. A similar copy number variant has been observed in individual(s) with propionic acidemia (PMID: 19157943; Invitae). This variant disrupts the p.Pro423 amino acid residue in PCCA. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 10518292, 20549364, 22033733). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="PCCA" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000013.10:g.(?_100953704)_(101077995_?)del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0268579" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB12974844</SubmissionName>
          <SubmissionName>SUB6933794</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="2357257" TraitType="Disease" MappingType="XRef" MappingValue="C0268579" MappingRef="MedGen">
        <MedGen CUI="C0268579" Name="Propionic acidemia" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

